<DOC>
	<DOC>NCT00216749</DOC>
	<brief_summary>This is a multicenter, open-label, prospective study of cilostazol use for prevention of recurrence in patients with cerebral infarction.</brief_summary>
	<brief_title>Efficacy and Safety of Cilostazol for the Indication of CSPS</brief_title>
	<detailed_description>This is a multicenter, open-label, prospective study of cilostazol use to prevention of recurrence in patients with cerebral infarction. Qualified patients will be treated with cilostazol by physician's assessment. This study will be continued for 4 years. More than 600 patients for 4 years.</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Patient with an experience of cerebral infarction and having a purpose for prevention of recurrence of cerebral infarction. Age: more than 18 years of age Unqualified patients judged by study investigator(s)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Cerebral Infarction Prevention</keyword>
	<keyword>Cilostazol</keyword>
</DOC>